Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Abstract NVA237 is a novel once-daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and bronchodilator efficacy of two doses of NVA237 (100 and 200 μg), versus placebo, in pa...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary pharmacology & therapeutics 2010-10, Vol.23 (5), p.438-444
Main Authors: Vogelmeier, C, Verkindre, C, Cheung, D, Galdiz, J.B, Güçlü, S.Z, Spangenthal, S, Overend, T, Henley, M, Mizutani, G, Zeldin, R.K
Format: Article
Language:English
Subjects:
Administration, Inhalation
Aged
Aged, 80 and over
Bronchodilator Agents - administration & dosage
Bronchodilator Agents - adverse effects
Bronchodilator Agents - therapeutic use
Chronic obstructive pulmonary disease
Double-Blind Method
Drug Administration Schedule
Female
Glycopyrrolate - administration & dosage
Glycopyrrolate - adverse effects
Glycopyrrolate - therapeutic use
Humans
Male
Medical Education
Middle Aged
Muscarinic antagonist
Muscarinic Antagonists - administration & dosage
Muscarinic Antagonists - adverse effects
Muscarinic Antagonists - therapeutic use
Nebulizers and Vaporizers
NVA237
Once-daily
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary/Respiratory
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract NVA237 is a novel once-daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and bronchodilator efficacy of two doses of NVA237 (100 and 200 μg), versus placebo, in patients with moderate-to-severe COPD (forced expiratory volume in 1 s [FEV1 ] ≥ 30% and
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2010.04.005